Mr. Erez Tetro reports

VVT MED SIGNS LARGEST EUROPEAN DISTRIBUTION AGREEMENT TO DATE; DISTRIBUTOR JOINS AS INVESTOR

VVT Med Inc. has entered into its largest European distribution agreement to date, a strategic exclusive distribution partnership with Uber Ros SpA for the commercialization of its ScleroSafe system in Italy, Vatican City and the Republic of San Marino.

Under the terms of the agreement, signed on April 9, 2026, Uber Ros will serve as the company's exclusive distributor in the territory. The five-year agreement represents approximately $2.3-million in potential revenue to the company, based on agreed minimum purchase commitments, with a portion structured under a pay-or-buy mechanism that provides a defined level of commercial commitment from the distributor, subject to the terms of the agreement.

Italy is a significant and strategically important health care market, with a well-established network of vascular and phlebology specialists. The partnership with Uber Ros enables VVT Med to access this market through an experienced and committed local commercial partner, supporting physician education and product adoption across the territory.

ScleroSafe is Food and Drug Administration-cleared and CE-marked, enabling its deployment within the European Union's regulatory framework. The company's NT-NT technology addresses the widest range of vein diameters, enabling physicians to treat both the medical and aesthetic aspects of venous disease through a proprietary, simultaneous sclerosant injection and blood aspiration process, with no anesthesia and no downtime

"We are very excited to begin this journey with VVT Med," said Giorgio Rosati, owner of Uber Ros SpA. "ScleroSafe integrates perfectly with our existing portfolio in the vascular segment and represents a natural extension of our offering to physicians.

"I am also particularly pleased that this agreement comes in a very special year for our company, as we celebrate our 40th anniversary. Over the years, Uber Ros has grown into one of the leading medical device distributors in Italy, representing highly prestigious international brands across multiple specialties, including vascular, orthopedics, trauma, spine, maxillofacial, ENT and neurosurgery.

"This partnership further strengthens our commitment to bringing innovative and effective solutions to the Italian health care system.

"This agreement marks another important step in executing our strategy to build a focused international distribution network with committed partners," said Erez Tetro, chief executive officer of VVT Med. "We believe Italy represents a compelling opportunity for ScleroSafe, and this partnership, our largest European agreement to date, reflects the growing commercial traction of our platform and the confidence that experienced regional partners are placing in our technology."

In addition to the commercial partnership, Uber Ros has joined the company's previously announced non-brokered private placement financing as an investor, further aligning commercial execution with strategic investment, subject to customary conditions and, where required, final acceptance by the TSX Venture Exchange. This participation reflects the conviction of the company's distribution partners in the long-term value of VVT Med's technology platform.

The offering remains subject to customary conditions and, where required, final acceptance by the TSX Venture Exchange. There can be no assurance that the full minimum purchase commitments will be realized or that the private placement will be completed on the terms described or at all.

Engagement of Arx as investor relations adviser

Pursuant to TSX-V Policy 3.4, VVT announces that it has engaged CapitaLynx Ltd. (Arx) to provide technology-powered investor relations services commencing on April 27, 2026, pursuant to the terms of an investor relations technologies and services agreement dated April 27, 2026, between VVT and Arx. The services to be provided by Arx include: press release and investor materials drafting and optimization; third party newswire distribution and reporter targeting; management of an investor relations inbox; and ancillary advisory support relating to capital markets and investor relations matters.

The agreement has an initial non-cancellable term of three months, during which the company is required to pay an aggregate fee of $37,500 (U.S.) ($12,500 (U.S.) per month), followed by automatic quarterly renewals at a fee of $12,500 (U.S.) per month ($37,500 (U.S.) per quarter). After the initial term the agreement shall automatically renew for successive quarterly periods, each consisting of three months and either party may terminate the agreement by providing no less than 30 days of prior written notice.

Arx is an arm's-length party to the company. Arx does not currently hold any securities of VVT Med.

About VVT Med Inc.

VVT Medical develops, manufactures and distributes minimally invasive, non-thermal, non-tumescent (NT-NT) solutions for the treatment of vein diseases, starting with varicose veins. VVT is the only FDA-cleared, stand-alone company offering NT-NT varicose vein treatment technology. VVT's FDA-cleared and CE-marked catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures with no anesthesia, no downtime, and minimal pain and side effects. Addressing the widest range of vein diameters, VVT's solutions empower patients by treating both the medical and aesthetic aspects of vein disease, while enabling physicians to deliver effective, efficient and cost-saving treatments through proprietary, simultaneous sclerosant injection and blood aspiration. The company's patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038.

We seek Safe Harbor.